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A B S T R A C T
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and one 
of the major risk factors for ischemic stroke and thromboembolic events. Vitamin K 
antagonists (VKA) are considered to be the cornerstone in antithrombotic therapy for 
many years. Alternatively, antithrombotic drugs such as aspirin or the combination of 
aspirin and clopidogrel are also used, but without having proved similar or superior 
in efficacy compared to VKA. Moreover, therapy with VKA has complications and 
it is also quite demanding, as it often requires close monitoring of anticoagulation 
therapy. Recently, newer anticoagulants have been developed, which include direct 
thrombin antagonists, such as dabigatran or factor Xa inhibitors, such as rivaroxaban, 
apixaban and edoxaban. For each of these novel drugs large phase III clinical trials 
have been completed and their results have already been published, with the excep-
tion of edoxaban. These drugs are more effective compared to conventional therapies 
and, furthermore, they lack the need for anticoagulation monitoring. With regards to 
their safety profile, it has been shown to be similar to VKA. Nevertheless, some re-
ports have recently emerged about fatal bleeding episodes after the use of dabigatran, 
which highlights the need for evidence based prescription of these novel drugs after 
thorough patient evaluation.
I N T R O D U C T I O N
Atrial fibrillation (AF) is the most commonly sustained tachyarrhythmia in the 
general population affecting about 1-2% of the general population.1 Its prevalence 
increases with the age from <0.5% at 40 – 50 years old, to 5-15% at 80 years old and 
it is estimated to be doubled in the next 50 years.2 Atrial fibrillation is associated with 
more hospitalizations, mainly due to ischemic strokes or chronic heart failure decom-
pensation. Ischemic strokes in association with AF are more severe and often fatal. In 
many cases, patients who survive are disabled and have a high probability for recurrent 
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episodes.3 Oral anticoagulant therapy (OAC) with vitamin K 
antagonists (VKAs) is considered to be the cornerstone for 
stroke prevention, in patients with AF and major risk factors.2 
Vitamin K antagonists, have proved their efficacy compared 
to placebo or no treatment, reducing the risk of stroke by 64% 
in patients with AF.4 Aspirin and clopidogrel, can be given 
to patients with minor risk factors, although their efficacy is 
significantly inferior compared to that of VKAs, according to 
the results of ACTIVE W study.5
However, daily clinical experience shows that the percent-
age of patients with AF, who need OAC but do not receive any 
medication, seems to be significant.6,7 Data from the BAFTA 
study showed that only 52% in the whole cohort were aware of 
the reasons for commencing their warfarin.8 Based on achiev-
ing a balance between stroke risk with low INR levels and an 
increasing bleeding risk with high INR levels, an INR of 2.0–3.0 
is the likely optimal range for the prevention of a stroke and 
systemic embolism in patients with AF. Over the recent years, 
new drugs for the prevention of thromboembolism in AF (da-
bigatran etexilate, apixaban, rivaroxaban, edoxaban etc.) have 
been evaluated in large clinical trials, regarding their efficacy 
and safety. The potential benefit of those drugs is mainly the 
lack of need for INR monitoring.
N E W  A N T I C O A G U L A N T S
Because of the difficulties of warfarin therapy and the 
continuous and increasing number of patients, who need 
anticoagulation therapy, the introduction of new drugs in 
the daily clinical practice was imperative. The aim was to 
produce medications, which fulfill the conditions for the ideal 
anticoagulant, as it has been established by clinical practice 
(Table 1). Two main classes of novel anticoagulants have been 
introduced in the clinical field targeting either the blockade 
of thrombin (IIa) or factor Xa in the coagulation cascade. 
Dabigatran etexilate is the main representative of the first class, 
while rivaroxaban, apixaban and edoxaban belong in the second 
class. All these novel drugs have reached phase III large mul-
ticenter prospective clinical trials for use in AF. The efficacy 
and the main side effects of these new compounds have been 
tested in clinical trials for venous thromboembolism, including 
patients undergoing orthopedic surgery.
D A B I G A T R A N  E T E X I L A T E
Dabigatran is a new oral pro-drug, which inhibits thrombin 
directly and reversibly. Its bioavailability is about 6.5% and 
the half time 12 to 17 hours, with mainly renal excretion.9 The 
clinical evaluation of the drug started firstly with large clinical 
trials (RE-NOVATE, RE-MODEL, RE-MOBILIZE trials) 
in orthopedic patients, investigating its potential thromboem-
bolism prevention effect, compared to enoxaparin. Noninfe-
riority and similar bleeding rates, compared to enoxaparin, 
were found in a pooled analysis of the results of these three 
trials.10 Subsequently, stroke prevention compared to warfarin 
in patients with AF was tested in the large phase III trial RE-
LY (Randomized Evaluation of Long-term anticoagulation 
therapy). Patients in this trial were randomized to receive, ei-
ther a fixed dose of dabigatran (110 or 150 mg bid), or warfarin 
with a target INR between 2.0 and 3.0 (Table 2). The primary 
endpoint was stroke or embolism and it occurred as often in 
patients receiving 110 mg dabigatran, as in patients receiving 
warfarin (1.5% vs. 1.7%, 95% confidence intervals-CI: 0.74 to 
1.11, RR:0.91, P=0.34) and less often in patients receiving 150 
mg dabigatran (1.1%, relative risk or risk ratio-RR: 0.66, 95% 
CI: 0.53 to 0.82, P<0.01).11 Analyzing this primary end point, 
compared to the time in therapeutic range (TTR) of patients, 
who are receiving warfarin, showed that the beneficial effects 
of dabigatran, were consistent regardless of INR control. 
Moreover, dabigatran was superior to warfarin regarding total 
mortality and cardiovascular events in patients with low TTR.12
The major bleeding risk was comparable in patients receiv-
ing dabigatran 150 mg bid and in patients receiving warfarin 
(RR: 0.93, 95% CI: 0.81 to 1.07, P=0.31), but lower in patients 
who were taking dabigatran 110 mg bid (RR: 0.80, 95% CI: 
0.69 to 0.93, P=0.003). Most importantly, the intracranial 
bleeding was reduced in both doses of dabigatran (0.3% and 
0.2% for 150 mg and 110 mg dosing, respectively) compared 
to warfarin (0.7%). However, dabigatran was associated, in 
a non-dose-dependent manner, with a small but significant 
increase in dyspepsia and a non significant increased rate of 
myocardial infarction compared to warfarin (0.7% vs. 0.5%, 
P=0.048 for 150 mg and P=0.07 for 110 mg).11
On the basis of the results of the RE-LY study in the recent 
guidelines issued by the European Society of Cardiology (ESC) 
for AF management, dabigatran is proposed as an alternative 
to warfarin therapy. In these guidelines, the HAS-BLED score 
has been introduced for the assessment of the patients’ bleed-
ing risk. Thus, in patients with low bleeding score (0-2) the 150 
mg bid dose is proposed, while the 110 mg dose is considered 
suitable in patients with higher score (≥3).13 The Food and 
Drug Administration (FDA) in the USA has approved the 
150 mg bid dose in high risk patients with AF and a reduced 
TABLE 1. Characteristics of the Ideal Anticoagulant
Oral administration preferably once daily at a fixed dose 
High degree of protection against stroke or embolism 
Predictable anticoagulant effect
No need of anticoagulation monitoring with blood tests
Low rate of bleeding episodes
No or little interaction with foods and other drugs
Low binding with plasma proteins
Low cost
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dosage of 75 mg bid in patients with severe renal insufficiency 
(creatinine clearance 15-30 ml/min).14 The Canadian Health 
Authority has also approved the 110 mg dose, which is rec-
ommended for patients with AF older than 80 years old and 
when the bleeding risk is high. In Europe, dabigatran (150 mg 
in low risk bleeding patients and 110 mg in high risk bleeding 
patients) has also gained approval for stroke prevention in 
patients with nonvalvular AF from the European Medicines 
Agency (EMA) on April 2011.15
R I VA R O X A B A N
Rivaroxaban is an anticoagulant agent, which inhibits 
directly the activated Xa factor, which is a key factor in the 
conversion of prothrombin to thrombin. It has a bioavailabil-
ity of 80% and is excreted mainly, approximately by 66%, by 
the liver without needing plasma coagulation monitoring. Its 
plasma half life is 7 to 11 hours but, due to its flat dose response 
and to the prolonged inhibition of Xa factor, it is administrated 
once daily.16 At first, rivaroxaban was approved for the preven-
tion of venous thromboembolism in patients after knee or hip 
replacement after an extensive clinical trial program, called 
RECORD, in which it was found to be non-inferior or even 
superior compared to enoxaparin.17
The effect of rivaroxaban in stroke prevention in AF was 
investigated in the ROCKET AF study (Rivaroxaban-once 
daily, oral, direct factor Xa inhibition compared with vitamin 
K antagonism for prevention of stroke and Embolism Trial 
in Atrial Fibrillation).18 In this phase III double blind study, 
14264, patients were randomized to receive either 20 mg ri-
varoxaban once a day (qd) or a dose-adjusted warfarin (INR 
target 2.0-3.0) and they were followed for a period of 24 months 
(Table 2). Rivaroxaban patients with renal insufficiency 
(creatinine clearance between 30 and 49 mL/min) received 
a reduced dose of 15 mg qd. Rivaroxaban was noninferior to 
warfarin for stroke or embolism in the primary analysis (1.7% 
per year) compared to the warfarin group (2.2% per year, 
P<0.001). However, conducting an intention-to-treat analysis, 
superiority was not established, although there was a trend but 
without statistical significance (2.12% per year for rivaroxaban 
vs. 2.42% per year for warfarin, P<0.001 for noninferiority; 
P=0.12 for superiority). In general, the bleeding rates were 
similar to warfarin but intracranial hemorrhage was lower in 
the rivaroxaban group (P=0.02).
Based on the similar efficacy and safety profile to warfarin, 
rivaroxaban was approved by the FDA on November 2011 
and by the EMA for stroke prevention in patients suffering 
from nonvalvular AF.19 The once-daily dosing regimen of 
rivaroxaban is perhaps an important advantage compared to 
dabigatran, although the results are tempered as the intensity 
of anticoagulation in ROCKET AF patients receiving warfarin 
was poorest (TTR range 55%) compared to other trials (the 
mean TTR in the RE–LY trial was 64%).11,18
A P I X A B A N
Another factor Xa inhibitor is apixaban, which has been 
evaluated by two large clinical trials, the ARISTOTLE and 
AVERROES for stroke prevention in patients with AF. The 
drug has a bioavailability of 50%, its plasma half life is about 
12 hours and it has multiple excretion pathways with renal 
clearance accounted for ~27% of total clearance.20 After the 
positive results of the clinical program ADVANCE 1 & 2 
(Apixaban Dosed orally Versus Anticoagulation with Inject-
able Enoxaparin to Prevent Thromboembolism), apixaban 
gained approval by the EMA for prevention of thromboem-
bolism, after knee or hip surgery in a dosage of 2.5 mg bid.21-23 
In the AVERROES trial, apixaban 5 mg bid was compared 
to aspirin 81-325 mg daily in patients with AF unsuitable for 
therapy with vitamin K antagonists. This trial was terminated 
early because apixaban displayed efficacy superior to aspirin 
regarding stroke or embolism (3.7%/year for aspirin vs. 1.6%/
year for apixaban, P<0.001), while no significant differences in 
major bleeding were evident (1.2%/year for aspirin vs. 1.4%/
year for apixaban, P=0.33).24 Apixaban efficacy in stroke pre-
vention was also compared to warfarin in the ARISTOTLE 
study, which enrolled patients with AF receiving either 5 mg 
of apixaban bid or warfarin (INR 2.0-3.0, mean TTR 62.2%). 
After a mean follow up of 1.1 years, apixaban was found to be 
noninferior and superior to warfarin for the primary outcome, 
reducing the risk of stroke or embolic events by 21% (P<0.01 
for noninferiority, P=0.01 for superiority). Apixaban showed 
significant better safety profile, compared to warfarin, for 
both major bleeding episodes and intracranial hemorrhage 
(P<0.001).25 Substudy data from the ARISTOTLE trial in 
patients with prior stroke or transient ischemic attack (TIA), 
showed a constant benefit of apixaban, compared to the gen-
eral study population (P=0.71).26 Likewise, apixaban seems 
to be similarly effective in patients with prior stroke or TIA 
in the AVERROES trial compared to the whole group of the 
study (P=0.17).27 Apixaban is under review by FDA for getting 
approval in the field of stroke prevention in patients with AF 
and the final decision is expected around March 2012.
E D O X A B A N
Edoxaban is a reversible direct inhibitor of factor Xa with 
good bioavailability and a plasma half time of 8-10 hours. It is 
mainly excreted by the renal system.28 It is one of the newest 
compounds in this category and a phase III trial (ENGAGE 
AF TIMI 48) is being conducted comparing edoxaban at two 
dosages, 30 and 60 mg qd, with INR adjusted warfarin dosage 
in patients with a minimum of 2 stroke risk factors other than 
AF. In this study, it is possible to reduce by the edoxaban dos-
age by 50% in patients with increased risk of bleeding, so it 
is the first study in this category of new anticoagulants, which 
is going to compare more than two dosages of the new drug 
with warfarin. The enrollment has been completed with 21,107 
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patients and the final completion of the trial is estimated in 
March 2012.29
A R E  T H E R E  A N Y  D I F F E R E N C E S 
B E T W E E N  T H E  N O V E L 
A N T I C O A G U L A N T S  I N  S A F E T Y  
A N D  E F F I C A C Y ?
It is a fact that, when drugs belonging to a new category 
are introduced in the clinical field, the question always arises, 
which of them is the safest and the most effective, compared 
to conventional therapies. Vitamin K antagonists have proved, 
for many years, their efficacy in the prevention of embolic 
events in patients with AF in clinical practice as well as through 
many clinical trials. The new thrombin and factor Xa inhibitors 
have advantages, as they can be prescribed in patients who 
are considered to be unsuitable for VKA therapy, and most 
importantly there is no need for a cumbersome INR monitor-
ing. As noted, in the RE-LY study dabigatran 150 mg bid was 
superior to warfarin; while apixaban was superior to warfarin 
and to aspirin in the ARISTOTLE and AVERROES stud-
ies, respectively. On one hand, rivaroxaban in the ROCKET 
AF study had superior efficacy compared to warfarin in the 
on-treatment analysis, but on the other hand, this was not 
confirmed in the intention-to-treat analysis. At this point it 
should be emphasized that the patient populations had differ-
ences in these trials (Table 2). Thus, the ROCKET AF study 
enrolled older patients (mean age 73 years), with at least two 
risk factors (congestive heart failure, hypertension, stroke or 
TIA), higher mean values of CHADS2 score (~3.5) and lower 
median TTR values for warfarin (58%) compared to other 
trials. Of course, it should also be emphasized that ROCKET 
AF patients’ characteristics, are more compatible with real life 
conditions, since the general population with AF is aged with 
comorbidities and always suboptimal INR values. Apixaban 
is the only novel anticoagulant, which in AVERROES trial 
was compared with aspirin in patients with mean CHADS2 
score of 2.1 unwilling or considered medically unsuitable for 
therapy with a VKA and showed superiority in the prevention 
of stroke or embolism without significant difference in bleeding 
events. According to the investigators of the study, apixaban is 
superior to the combination of clopidogrel plus aspiring (study 
ACTIVE A) and non inferior to warfarin, which was proved 
with the results of the ARISTOTLE study.30
With regards to the adverse effects of these drugs, the main 
problem that remains is the bleeding episodes, which in the 
case of intracranial hemorrhage for example would be fatal. 
Dabigatran 110 mg bid in the RE-LY trial caused significant 
fewer bleedings, compared to warfarin, while rivaroxaban in 
the ROCKET AF study had similar bleeding rates to warfarin 
with significant fewer intracranial hemorrhages. Apixaban 
seemed to be safer compared to warfarin in this field in the 
ARISTOTLE study and similar to aspirin in the AVERROES 
study. The clinical practice of course is many times different 
than clinical trial conditions, especially when a new drug is 
introduced in the market. Thus, although the latest guidelines 
from the American College of Cardiology have proposed 
dabigatran 150 mg as a class I anticoagulant drug for patients 
with nonvalvular AF with same safety profile to warfarin, dur-
ing the last several months several cases of serious bleedings 
have been described. Thus, the EMA issued in November 2011 
an update reporting 256 fatal bleeding cases worldwide (21 
of them in Europe) and focusing in the assessment of renal 
function before starting treatment with dabigatran.31 Likewise, 
a few days later the FDA issued a similar warning concern-
ing the safety of dabigatran.32 Concerns about bleeding have 
continued and the Institute of Safe Medication Practices in 
USA announced that dabigatran adverse reactions involving 
bleeding were higher compared to warfarin in the first quarter 
of 2011, with a considerable percentage of intracranial hemor-
rhage in the elderly patients.33 One other issue that is unclear 
is the periprocedural efficacy and adverse effects of the new 
OACs. The results of a recently published small prospective 
trial, showed that in patients undergoing AF ablation, con-
tinuation of dabigatran during the periprocedural period is 
associated with an increased risk of bleeding (14% vs. 6%, 
P=0.031) and composite of bleeding or embolic complica-
tions (16% vs. 6%; P=0.009) compared with uninterrupted 
warfarin therapy.34 Obviously, a serious disadvantage of these 
compounds, mainly for patients with comorbidities, is that in 
case of serious bleeding, there is no effective antidote like 
vitamin K for VKA. Dabigatran can be eliminated either by 
dialysis, or after administrating charcoal within 2 hours after 
the last dose.35 In contrast, rivaroxaban and apixaban cannot 
be eliminated by dialysis due to their binding to proteins. A 
small study showed that prothrombin complex concentrate 
(PCC) could to be an effective antidote for rivaroxaban, but 
not for dabigatran. Similarly, recently published data from an 
in vitro study indicate that PCC and recombinant factor VIIa 
significantly reversed the anticoagulant effect of edoxaban.37
C O N C L U S I O N
It is clear that the need of new oral anticoagulants for the 
prevention of stroke in AF is undeniable as the population 
of patients is growing and there is a tendency to adopt more 
convenient therapies. Recently, data from a meta-analysis 
showed that self-monitoring of oral anticoagulation was not 
significantly superior to usual care in reducing thromboembolic 
events in patients with AF, when the difference was superior 
in young people with prosthetic valves.38 According to investi-
gators, patients with AF were mostly older and not aware for 
the thromboembolic risk of AF, compared to patients with 
prosthetic valves. Prescription for the new OACs must be car-
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ried out after first assessing the profile of each patient and the 
potential hazard of stroke and bleeding using CHADS2VASC 
and HAS-BLED scores. However, patients with labile INRs 
are not necessarily the best candidates for the new OACs 
either, especially if the underlying reason is poor compliance, 
particularly, as the new OACs have relatively short half-lives 
and omission of doses can be catastrophic. Finally, financial 
issues are very important, and the cost-effectiveness analyses 
for the new OACs have to include not only the price of the 
drug, but also the costs of the whole spectrum of anticoagula-
tion monitoring which is necessary for VKA.39,40
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